scholarly journals Nicolau syndrome following intramuscular benzathine penicillin injection: a case report

2020 ◽  
Vol 37 ◽  
Author(s):  
Walaza Phiri ◽  
Maen Shulammite Musonda ◽  
Kebby Kyakilika ◽  
Michelo Haluuma Miyoba ◽  
Malan Malumani
2014 ◽  
Vol 8 (1) ◽  
Author(s):  
İnci Kılıç ◽  
Füruzan Kaya ◽  
Ayşe T Özdemir ◽  
Tuğba Demirel ◽  
İlhami Çelik

PEDIATRICS ◽  
1976 ◽  
Vol 57 (4) ◽  
pp. 573-574
Author(s):  
James W. Renne ◽  
Herbert B. Tanowitz ◽  
Jeffrey D. Chulay

Clostridium ghoni and Hemophilus parainfluenzae are uncommon causes of human infection. Both of these agents were isolated from joint fluid in a child with septic arthritis. CASE REPORT An 8-month-old white girl was admitted with a three-day history of irritability, fever, and inability to lie on her right side. Ten days prior to admission bilateral otitis media was treated with 600,000 units of benzathine penicillin intramuscularly and sulfisoxazole suspension (1 gm daily until admission). Fever and irritability from otitis abated by the fifth day of therapy. On admission the infant appeared acutely ill and had a temperature of 39.7 C.


2016 ◽  
Vol 15 (1) ◽  
pp. 70-73 ◽  
Author(s):  
Carlos Alberto Araujo Chagas ◽  
Tulio Fabiano de Oliveira Leite ◽  
Lucas Alves Sarmento Pires

Abstract We report on the case of a 40-year-old male who was admitted to the clinic with a large ulcer on his left buttock, 3 days after an intramuscular benzathine penicillin injection. The patient was diagnosed with Nicolau syndrome, a rare vascular complication in which a lesion develops after intramuscular injection. Symptoms are intense pain at the injection site, erythema, and livedoid dermatitis, which leads to necrosis of skin, subcutaneous tissue and muscle tissue. It was described by Nicolau after intramuscular injections of bismuth salt for syphillis therapy. Nicolau syndrome is rare, but its symptoms are devastating and healthcare professionals must be aware of this clinical entity, since intramuscular injections are common procedures for administration of drugs.


2021 ◽  
Vol 64 ◽  
pp. 101597
Author(s):  
Yapo Guy serge Kouamé ◽  
Jean Baptiste Yaokreh ◽  
Moufidath Sounkeré ◽  
Samba Tembely ◽  
Idalia Taguela Ajoumissi ◽  
...  

2020 ◽  
Vol 7 (1) ◽  
pp. 88-93
Author(s):  
Luis de Almeida Maia ◽  
Olga Pereira ◽  
Ricardo Marta ◽  
Joana Costa ◽  
Ana Batista ◽  
...  

BMC Neurology ◽  
2015 ◽  
Vol 15 (1) ◽  
Author(s):  
Chiara Zecca ◽  
Carlo Mainetti ◽  
Roland Blum ◽  
Claudio Gobbi

2016 ◽  
Vol 10 (2) ◽  
pp. 193 ◽  
Author(s):  
Piyush N Kalani ◽  
Harsha D Makwana ◽  
Kamlesh P Patel ◽  
Supriya Malhotra ◽  
Advait V Thakor ◽  
...  

2016 ◽  
Vol 8 (3) ◽  
pp. 333-340 ◽  
Author(s):  
Maria A. Barnadas ◽  
Montserrat M. Díaz Encarnación

Background: Omega-3 fatty acids (O3FA) have been used to treat IgA nephropathy (IgAN) but not cutaneous IgA vasculitis (IgAV). Case Report: A 47-year-old female was referred for cutaneous vasculitis. She had a 24-year history of flares of palpable purpura, arthralgia associated with hematuria, and proteinuria. We diagnosed cutaneous IgAV associated with IgAN. We administered prednisone at doses ranging from 10 to 45 mg/day to control the flares. To reduce prednisone exposure, different therapeutic strategies (colchicine, diphenhydramine, hydroxyzine, azathioprine, benzathine penicillin, and mycophenolate mofetil) were applied without success. After 11 years, therapy with O3FA capsules containing 460 mg eicosapentaenoic acid and 380 mg of docosahexaenoic acid t.i.d. was introduced, allowing the prednisone to be stopped 2 years later. When the dose of O3FA was decreased to 1 capsule on alternate days, the cutaneous flares reappeared, but they were again controlled when the patient took 1 O3FA capsule daily. Conclusions: O3FA can be useful to control cutaneous IgAV.


Sign in / Sign up

Export Citation Format

Share Document